Federal Contractor Profile
Resilience Government Services, INC.
$291.8M obligated·18 awards·2 agencies·5 NAICS
Federal Contracts
Showing contracts 1–50 of 81 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 23, 2025 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $1.6M |
| Sep 10, 2024 | Department of DefenseW6QK ACC-APG | W911SR23F0057 | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $4.5M |
| Jul 31, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $750K |
| Jun 25, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023F00001 | 541711 | DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT | $314K |
| May 23, 2024 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $9.0M |
| Mar 28, 2024 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $3.0M |
| Mar 26, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $473K |
| Feb 21, 2024 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $9.1M |
| Nov 2, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0073 | 541715 | DS PROCESS CHARACTERIZATION | $1000K |
| Nov 1, 2023 | Department of DefenseW6QK ACC-APG | W911SR23F0057 | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $2.2M |
| Oct 30, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $2.8M |
| Sep 25, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $489K |
| Sep 12, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.8M |
| Aug 25, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023F00001 | 541711 | DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT | $485K |
| Aug 17, 2023 | Department of DefenseW6QK ACC-APG | W911SR23F0057 | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $135K |
| Aug 8, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $4.8M |
| Aug 3, 2023 | Department of DefenseW6QK ACC-APG | W911SR23F0057 | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $400K |
| Aug 3, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0073 | 541715 | DS PROCESS CHARACTERIZATION | $1.1M |
| Jun 29, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $4.4M |
| Jun 23, 2023 | Department of DefenseW6QK ACC-APG | W911SR23F0057 | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $681K |
| Apr 12, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $9.8M |
| Mar 9, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $12.5M |
| Mar 8, 2023 | Department of DefenseW6QK ACC-APG | W911SR23F0057 | 541715 | DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT. | $4.4M |
| Mar 7, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0073 | 541715 | DS PROCESS CHARACTERIZATION | $2.0M |
| Feb 17, 2023 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $5.6M |
| Feb 13, 2023 | Department of DefenseW6QK ACC-APG | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $81K |
| Feb 9, 2023 | Department of DefenseW6QK ACC-APG | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $123K |
| Nov 30, 2022 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $3.0M |
| Aug 1, 2022 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $2.3M |
| Jun 30, 2022 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $21.1M |
| Jun 16, 2022 | Department of DefenseW6QK ACC-APG | W911SR22F0073 | 541715 | DS PROCESS CHARACTERIZATION | $2.4M |
| Apr 30, 2022 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $22.0M |
| Feb 22, 2022 | Department of DefenseW6QK ACC-APG | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $1.8M |
| Jan 5, 2022 | Department of DefenseW6QK ACC-APG | W911SR22F0014 | 541715 | CLINICAL DEVELOPMENT PHASE 2 STUDY | $18.7M |
| Dec 18, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $272K |
| Jun 24, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $612K |
| Feb 19, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.6M |
| Feb 17, 2021 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $1.9M |
| Dec 16, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0101 | 325412 | FILL AND FINISH CAPACITY | $39.0M |
| Sep 7, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $1.1M |
| Aug 17, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY20C0101 | 325412 | FILL AND FINISH CAPACITY | $53.1M |
| Aug 4, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $1.2M |
| Jun 10, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $800K |
| May 14, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $680K |
| Apr 15, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $485K |
| Mar 4, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00057 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $1.8M |
| Feb 25, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $1.0M |
| Feb 18, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY19C0049 | 541714 | PMR AND PMC | $125K |
| Dec 31, 2019 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $2.4M |
| Dec 13, 2019 | Department of DefenseW6QK ACC-APG NATICK | W911QY13C0010 | 325412 | MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY | $1.3M |
Get Alerted Before Resilience Government Services, INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free